{"id":"raptiva","rwe":[],"tags":[],"phase":"discontinued","safety":{"boxedWarnings":[],"safetySignals":[],"drugInteractions":[],"commonSideEffects":[],"contraindications":[],"specialPopulations":{},"discontinuationRates":[],"seriousAdverseEvents":[]},"status":"discontinued","trials":["NCT00602823","NCT00276250","NCT00746980","NCT00972543","NCT00254982","NCT00287118","NCT00739882","NCT00338143","NCT00368654","NCT00402818","NCT00051662","NCT01079988","NCT00096603","NCT00336973","NCT00280826","NCT00707070","NCT01848028","NCT00134134","NCT00489216","NCT00312026","NCT00442650","NCT00672204","NCT00726466","NCT00777400","NCT00608777","NCT00510536","NCT00115076","NCT00344448","NCT00302445","NCT00382512","NCT00308204","NCT00501709","NCT00472082","NCT00097240","NCT00109252","NCT00096928","NCT00669214","NCT00697593","NCT00146003","NCT00249808","NCT00034203","NCT00109317","NCT00226057","NCT00256139","NCT00737763","NCT00184366","NCT00133107","NCT02075697","NCT00729768","NCT00096980"],"aliases":["efalizumab","anti-CD11a monoclonal antibody","Efalizumab"],"patents":[],"pricing":[],"offLabel":[],"timeline":[],"brandName":"Raptiva","companyId":"national-institute-of-dental-and-craniofacial-research-nidcr","ecosystem":[],"mechanism":{"target":"Leukocyte adhesion glycoprotein LFA-1 alpha","novelty":"","modality":"Small molecule","drugClass":"","explanation":"","oneSentence":"","technicalDetail":""},"commercial":null,"references":[],"biosimilars":[],"companyName":"National Institute of Dental and Craniofacial Research (NIDCR)","competitors":[],"dataSources":[{"url":"https://clinicaltrials.gov","name":"ClinicalTrials.gov","fields":["trialDetails","trials"],"retrievedDate":"2026-04-07"},{"url":"https://drugcentral.org","name":"DrugCentral","fields":["indications","contraindications","safety","target","drugInteractions"],"retrievedDate":"2026-04-07"}],"genericName":"Raptiva","indications":{"approved":[{"name":"Plaque psoriasis","diseaseId":"plaque-psoriasis","approvalDate":"","lineOfTherapy":"","approvalCountry":"United States"}],"offLabel":[],"pipeline":[]},"labelChanges":[],"relatedDrugs":[],"trialDetails":[{"nctId":"NCT00602823","phase":"N/A","title":"Ex Vivo Monocyte and Lymphocyte Stimulation Tests and Genomic Study for the Prediction of Efficacy and Adverse Effects of CD11a Monoclonal Antibodies(Raptiva)","status":"COMPLETED","sponsor":"National Taiwan University Hospital","isPivotal":false,"enrollment":20,"indication":"Psoriasis","completionDate":"2006-05"},{"nctId":"NCT00276250","phase":"Phase 2","title":"Development of Immunosuppression Regimens to Facilitate Single Donor Islet Transplantation Using Abatacept","status":"COMPLETED","sponsor":"Emory University","isPivotal":false,"enrollment":5,"indication":"Type 1 Diabetes Mellitus","completionDate":"2014-12"},{"nctId":"NCT00746980","phase":"Phase 2","title":"Efalizumab in the Treatment of Alopecia Totalis/Universalis in Young Adults, Phase II","status":"WITHDRAWN","sponsor":"Northwestern University","isPivotal":false,"enrollment":0,"indication":"Alopecia Totalis","completionDate":"2009-07"},{"nctId":"NCT00972543","phase":"Phase 4","title":"A Phase IV Multicentre, Randomized Double-blind, Placebo-controlled Trial to Evaluate the Safety and Efficacy of Raptiva in the Treatment of Subjects With Moderate to Severe Chronic Plaque Psoriasis I","status":"TERMINATED","sponsor":"Merck KGaA, Darmstadt, Germany","isPivotal":false,"enrollment":6,"indication":"Chronic Plaque Psoriasis","completionDate":""},{"nctId":"NCT00254982","phase":"Phase 3","title":"An Open-Label Study to Determine Equivalence in Efficacy, Organ Safety and Systemic Tolerability Between Infliximab in GROUP I (\"High Need\") and GROUP II (\"Low Need\") Patients Suffering From Chronic P","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","isPivotal":true,"enrollment":593,"indication":"Psoriasis","completionDate":"2006-09"},{"nctId":"NCT00287118","phase":"Phase 4","title":"A Multicentre, Open Label Phase IIIb/IV Study of Subcutaneously Administered Raptiva in the Treatment of Adult Subjects With Moderate to Severe Plaque Psoriasis","status":"COMPLETED","sponsor":"Merck KGaA, Darmstadt, Germany","isPivotal":false,"enrollment":189,"indication":"Candidates for Systemic Therapy for Psoriasis, Psoriasis","completionDate":"2006-05-30"},{"nctId":"NCT00739882","phase":"Phase 4","title":"A Phase IV Multicentre, Randomised, Double-blind, Placebo Controlled, Trial to Evaluate the Safety and Efficacy of Raptiva ® in the Treatment of Subjects With Moderate to Severe Plaque Psoriasis Invol","status":"TERMINATED","sponsor":"Merck KGaA, Darmstadt, Germany","isPivotal":false,"enrollment":76,"indication":"Chronic Plaque Psoriasis","completionDate":"2009-06"},{"nctId":"NCT00338143","phase":"Phase 3","title":"A Phase IIIb, Open-Label, Multicenter Study to Evaluate the Safety of 1.0 mg/kg Subcutaneously Administered Efalizumab in Adults With Moderate to Severe Plaque Psoriasis, Including Those Who Are Recei","status":"COMPLETED","sponsor":"Genentech, Inc.","isPivotal":true,"enrollment":1200,"indication":"Psoriasis","completionDate":"2004-05"},{"nctId":"NCT00368654","phase":"Phase 1","title":"An Open-Label Study to Evaluate Whether a Short-Term Course of Methotrexate in Psoriasis Patients Treated With Efalizumab is Safe and Increases Efficacy","status":"COMPLETED","sponsor":"University of California, Davis","isPivotal":false,"enrollment":12,"indication":"Psoriasis","completionDate":"2008-05"},{"nctId":"NCT00402818","phase":"N/A","title":"RESTORE (Raptiva® (Efalizumab) Evaluation of Safety and Treatment Optimization Registry) Observational, Open-label, Multi-centre, Phase IV Study of Subcutaneously Administered Raptiva® (Efalizumab) in","status":"TERMINATED","sponsor":"Merck KGaA, Darmstadt, Germany","isPivotal":false,"enrollment":294,"indication":"Plaque Psoriasis","completionDate":"2009-07"},{"nctId":"NCT00051662","phase":"Phase 1","title":"A Phase II, Randomized, Double-Blind, Placebo-Controlled Study to Determine the Safety, Efficacy and Pharmacokinetics of Efalizumab in Subjects With Psoriatic Arthritis","status":"COMPLETED","sponsor":"XOMA (US) LLC","isPivotal":false,"enrollment":45,"indication":"Psoriatic Arthritis","completionDate":"2004-02"},{"nctId":"NCT01079988","phase":"Phase 4","title":"A Phase IV Open Label, Multicentre, Investigational Study of the Therapeutic Options for Subjects Discontinuing Efalizumab Therapy and Experiencing Inflammatory Disease Recurrence","status":"COMPLETED","sponsor":"Merck KGaA, Darmstadt, Germany","isPivotal":false,"enrollment":41,"indication":"Psoriasis","completionDate":"2005-04"},{"nctId":"NCT00096603","phase":"Phase 3","title":"An Open Label, Multicenter Study to Evaluate the Safety of 1.0 mg/kg Subcutaneously Administered Efalizumab in Adults With Plaque Psoriasis Previously Enrolled in Study ACD2600g","status":"COMPLETED","sponsor":"Genentech, Inc.","isPivotal":true,"enrollment":450,"indication":"Psoriasis","completionDate":"2004-07"},{"nctId":"NCT00336973","phase":"Phase 4","title":"A Phase IV Open-Label Study to Evaluate the Efficacy and Safety of 1.0 mg/kg Raptiva (Efalizumab) in Adult Subjects With Chronic Moderate or Worse Plaque Psoriasis Who Have Had an Inadequate Response ","status":"COMPLETED","sponsor":"Genentech, Inc.","isPivotal":false,"enrollment":73,"indication":"Psoriasis","completionDate":""},{"nctId":"NCT00280826","phase":"Phase 1","title":"Treatment of Non-Infectious Intermediate and Posterior Uveitis Associated Macular Edema With Humanized Anti-CD11a Antibody Therapy","status":"COMPLETED","sponsor":"National Eye Institute (NEI)","isPivotal":false,"enrollment":6,"indication":"Uveitis, Macular Edema","completionDate":"2009-02"},{"nctId":"NCT00707070","phase":"Phase 4","title":"Phase IV Study on Efficacy and Safety of the Combination Treatment Acitretin and Efalizumab in Moderate to Severe Chronic Plaque Psoriasis","status":"UNKNOWN","sponsor":"Universita di Verona","isPivotal":false,"enrollment":100,"indication":"Chronic Plaque Psoriasis","completionDate":"2009-10"},{"nctId":"NCT01848028","phase":"N/A","title":"Long-Term Benefits and Safety of Systemic Psoriasis Therapy: German Registry on the Treatment of Psoriasis With Biologics and Systemic Therapeutics","status":"RECRUITING","sponsor":"Universitätsklinikum Hamburg-Eppendorf","isPivotal":false,"enrollment":3500,"indication":"Psoriasis, Psoriatic-arthritis","completionDate":"2032-12"},{"nctId":"NCT00134134","phase":"Phase 1","title":"An Open-Label Assessment of the Efficacy & Safety of Efalizumab in the Treatment of Moderate-Severe Hydradenitis Suppurativa","status":"COMPLETED","sponsor":"NYU Langone Health","isPivotal":false,"enrollment":5,"indication":"Hidradenitis Suppurativa","completionDate":"2006-08"},{"nctId":"NCT00489216","phase":"NA","title":"Weekly Subcutaneous Efalizumab for the Treatment of Steroid Refractory Graft-Versus-Host Disease of the Skin and Liver","status":"TERMINATED","sponsor":"UNC Lineberger Comprehensive Cancer Center","isPivotal":false,"enrollment":2,"indication":"Graft Versus Host Disease","completionDate":"2008-10"},{"nctId":"NCT00312026","phase":"Phase 4","title":"A Phase IV Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of 1.0 mg/kg Efalizumab in Adult Patients With Moderate to Severe Plaque Psoriasis Involving the Hands","status":"COMPLETED","sponsor":"Genentech, Inc.","isPivotal":false,"enrollment":75,"indication":"Psoriasis","completionDate":"2006-11-28"},{"nctId":"NCT00442650","phase":"Phase 3","title":"","status":"COMPLETED","sponsor":"Merck KGaA, Darmstadt, Germany","isPivotal":true,"enrollment":0,"indication":"Moderate to Severe Psoriasis","completionDate":"2005-12"},{"nctId":"NCT00672204","phase":"Phase 1","title":"Efalizumab (Raptiva) Combined With Sirolimus in Type 1 Diabetic Islet Allograft Recipients","status":"TERMINATED","sponsor":"University of Minnesota","isPivotal":false,"enrollment":23,"indication":"Type 1 Diabetes Mellitus, Hypoglycemia","completionDate":"2012-08"},{"nctId":"NCT00726466","phase":"Phase 1","title":"A Phase I Study of the Inhibition of LFA-1 to Intercellular Adhesion Molecule-1 (ICAM-1) Using Subcutaneous Efalizumab Combined With Intravitreal Ranibizumab in the Treatment of Age-Related Macular De","status":"WITHDRAWN","sponsor":"Vitreous -Retina- Macula Consultants of New York","isPivotal":false,"enrollment":0,"indication":"Age Related Macular Degeneration, AMD","completionDate":""},{"nctId":"NCT00777400","phase":"Phase 1","title":"A Pilot Trial to Assess the Effect of CNI Conversion to Efalizumab in T Regulatory Cells in Renal Transplantation","status":"WITHDRAWN","sponsor":"University of California, San Francisco","isPivotal":false,"enrollment":0,"indication":"Autoimmune Diseases","completionDate":"2009-04"},{"nctId":"NCT00608777","phase":"Phase 4","title":"Effect of Topical Calcipotriene/Betamethasone (Taclonex) in Managing Localized Mild Breakthrough in Moderate to Severe Plaque Psoriasis Patients Receiving Efalizumab ( Raptiva).","status":"TERMINATED","sponsor":"Derm Research, PLLC","isPivotal":false,"enrollment":6,"indication":"Plaque Psoriasis","completionDate":"2009-02"},{"nctId":"NCT00510536","phase":"Phase 4","title":"A Phase 4 Study to Assess the Practical Management of Mild to Moderate Arthritic or Arthralgic Events in Patients With Chronic Plaque Psoriasis Receiving Efalizumab","status":"COMPLETED","sponsor":"Probity Medical Research","isPivotal":false,"enrollment":50,"indication":"Arthritis, Arthralgia","completionDate":"2008-10"},{"nctId":"NCT00115076","phase":"Phase 3","title":"A Phase IIIB Study to Evaluate the Mechanism of Action of 1.0 mg/kg Subcutaneously Administered Efalizumab in Adults With Moderate to Severe Plaque Psoriasis Who Are Candidates for Systemic Therapy","status":"COMPLETED","sponsor":"Rockefeller University","isPivotal":true,"enrollment":31,"indication":"Psoriasis","completionDate":"2011-04-06"},{"nctId":"NCT00344448","phase":"Phase 2","title":"A Randomized, Placebo Controlled, Proof of Concept, Study of Raptiva, a Humanized Anti-CD-11a Monoclonal Antibody, in Patients With Sjogren's Syndrome","status":"TERMINATED","sponsor":"National Institute of Dental and Craniofacial Research (NIDCR)","isPivotal":false,"enrollment":10,"indication":"Sjogren's Syndrome","completionDate":"2009-01"},{"nctId":"NCT00302445","phase":"Phase 4","title":"An Open-Label Pilot Study to Evaluate the Efficacy and Safety of Raptiva (Efalizumab)in Combination With Narrow Band Phototherapy for the Treatment of Moderate to Severe Plaque Psoriasis.","status":"COMPLETED","sponsor":"Derm Research, PLLC","isPivotal":false,"enrollment":20,"indication":"Plaque Psoriasis","completionDate":"2007-07"},{"nctId":"NCT00382512","phase":"Phase 1","title":"A Randomized, Placebo-Controlled, Single-Blind, Parallel-Group Study to Evaluate the Effects of 12 Weekly Subcutaneous Doses of 1.0 mg/kg Efalizumab on Immune Responses in Subjects With Moderate Plaqu","status":"COMPLETED","sponsor":"Genentech, Inc.","isPivotal":false,"enrollment":60,"indication":"Plaque Psoriasis","completionDate":""},{"nctId":"NCT00308204","phase":"Phase 2","title":"Discoid Lupus Erythematosus of the Scalp and a Trial of Biologic Therapy With Raptiva","status":"WITHDRAWN","sponsor":"The Cleveland Clinic","isPivotal":false,"enrollment":0,"indication":"Discoid Lupus Erthematosus of the Scalp","completionDate":"2007-08"},{"nctId":"NCT00501709","phase":"Phase 1","title":"Prevention of Autoimmune Destruction and Rejection of Human Pancreatic Islets Following Transplantation for Insulin Dependent Diabetes Mellitus","status":"COMPLETED","sponsor":"University of California, San Francisco","isPivotal":false,"enrollment":10,"indication":"Type 1 Diabetes","completionDate":"2016-12"},{"nctId":"NCT00472082","phase":"Phase 1","title":"An Open Label, Single-Center Pilot Study of Early Conversion From Tacrolimus to Efalizumab Maintenance Therapy in Primary Renal Transplant Recipients","status":"TERMINATED","sponsor":"Emory University","isPivotal":false,"enrollment":5,"indication":"Kidney Transplantation, Chronic Kidney Failure","completionDate":"2009-04"},{"nctId":"NCT00097240","phase":"N/A","title":"The Raptiva Pregnancy Registry: An Observational Study of the Use and Safety of Raptiva (Efalizumab) During Pregnancy","status":"COMPLETED","sponsor":"Genentech, Inc.","isPivotal":false,"enrollment":18,"indication":"Psoriasis, Pregnancy","completionDate":"2009-09"},{"nctId":"NCT00109252","phase":"Phase 3","title":"An Open-Label, Multicenter Study to Evaluate the Efficacy and Safety of 1.0 mg/kg Subcutaneously Administered Efalizumab Followed by Efalizumab Taper in Adults With Plaque Psoriasis Previously Enrolle","status":"COMPLETED","sponsor":"Genentech, Inc.","isPivotal":true,"enrollment":0,"indication":"Psoriasis","completionDate":"2003-04"},{"nctId":"NCT00096928","phase":"N/A","title":"Raptiva Epidemiologic Study of Psoriasis Outcomes and Safety Events in Patients With Chronic Moderate to Severe Plaque Psoriasis (RESPONSE)","status":"COMPLETED","sponsor":"Genentech, Inc.","isPivotal":false,"enrollment":1846,"indication":"Psoriasis","completionDate":"2009-10"},{"nctId":"NCT00669214","phase":"Phase 4","title":"A Phase IV Randomized, Double-Blind, Placebo Controlled Study to Evaluate the Safety and Efficacy of 1.0 mg/kg Efalizumab in Adult Patients With Moderate to Severe Plaque Psoriasis With Involvement of","status":"COMPLETED","sponsor":"Genentech, Inc.","isPivotal":false,"enrollment":89,"indication":"Psoriasis","completionDate":"2009-01"},{"nctId":"NCT00697593","phase":"Phase 4","title":"A Phase IV Open Label Study in Moderate to Severe Chronic Plaque Psoriasis Subjects Transitioning From Previous Systemic Antipsoriasis Therapies (Methotrexate, Cyclosporine, Retinoids or Psoralen-Ultr","status":"TERMINATED","sponsor":"Merck KGaA, Darmstadt, Germany","isPivotal":false,"enrollment":70,"indication":"Chronic Plaque Psoriasis","completionDate":"2009-04"},{"nctId":"NCT00146003","phase":"Phase 2","title":"Investigator-Initiated Trial of Efalizumab for Atopic Dermatitis: A Proof of Concept Study in Adults","status":"COMPLETED","sponsor":"University of Medicine and Dentistry of New Jersey","isPivotal":false,"enrollment":10,"indication":"Dermatitis, Atopic","completionDate":"2007-12"},{"nctId":"NCT00249808","phase":"Phase 4","title":"A Multicentre, Open Label Phase IIIb/IV Study of Subcutaneously Administered Efalizumab in the Treatment of Adult Patients With Moderate to Severe Chronic Plaque Psoriasis Who Have Failed to Respond t","status":"COMPLETED","sponsor":"Merck KGaA, Darmstadt, Germany","isPivotal":false,"enrollment":1266,"indication":"Psoriasis","completionDate":"2007-01-25"},{"nctId":"NCT00034203","phase":"Phase 2","title":"","status":"COMPLETED","sponsor":"XOMA (US) LLC","isPivotal":false,"enrollment":0,"indication":"Rheumatoid Arthritis","completionDate":"2003-08"},{"nctId":"NCT00109317","phase":"Phase 3","title":"A Phase IIIb, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled, Multicenter Study to Evaluate the Safety of 1.0 mg/kg Subcutaneously Administered Efalizumab in Adults With Moderate to Seve","status":"COMPLETED","sponsor":"Genentech, Inc.","isPivotal":true,"enrollment":686,"indication":"Psoriasis","completionDate":"2003-02"},{"nctId":"NCT00226057","phase":"Phase 1","title":"Efalizumab for Moderate to Severe Atopic Dermatitis - A Phase I Pilot Study in Adults","status":"COMPLETED","sponsor":"Oregon Health and Science University","isPivotal":false,"enrollment":10,"indication":"Dermatitis, Atopic","completionDate":"2006-05"},{"nctId":"NCT00256139","phase":"Phase 3","title":"","status":"COMPLETED","sponsor":"Merck KGaA, Darmstadt, Germany","isPivotal":true,"enrollment":793,"indication":"Moderate to Severe Psoriasis","completionDate":"2004-10"},{"nctId":"NCT00737763","phase":"Phase 2","title":"Beta Cell Rescue in New Onset Type 1 Diabetes Mellitus With the LFA-1 Antibody Efalizumab","status":"WITHDRAWN","sponsor":"Emory University","isPivotal":false,"enrollment":0,"indication":"Diabetes Mellitus, Type 1","completionDate":"2009-11"},{"nctId":"NCT00184366","phase":"N/A","title":"Classification and Characterization of Patients Suffering From Moderate to Severe Plaque Psoriasis Responding to Subcutaneous Administered Efalizumab","status":"TERMINATED","sponsor":"Norwegian University of Science and Technology","isPivotal":false,"enrollment":96,"indication":"Plaque Psoriasis","completionDate":"2008-07"},{"nctId":"NCT00133107","phase":"NA","title":"A Single Center, Open-label, Pilot Study Evaluating the Safety and Effectiveness of Subcutaneous Efalizumab in the Treatment of Oral Lichen Planus","status":"COMPLETED","sponsor":"Washington University School of Medicine","isPivotal":false,"enrollment":4,"indication":"Lichen Planus, Oral","completionDate":"2005-11"},{"nctId":"NCT02075697","phase":"N/A","title":"Spanish Registry of Systemic Treatments in Psoriasis","status":"UNKNOWN","sponsor":"Fundación Academia Española de Dermatología","isPivotal":false,"enrollment":3500,"indication":"Psoriasis","completionDate":"2025-10"},{"nctId":"NCT00729768","phase":"Phase 2","title":"A Phase II/III, Randomized, Open-Label, Active Controlled, Multicenter Trial to Evaluate the Safety and Efficacy of Efalizumab Compared With Cyclosporine, Both in Combination With Mycophenolate Mofeti","status":"WITHDRAWN","sponsor":"Genentech, Inc.","isPivotal":true,"enrollment":0,"indication":"Kidney Transplantation","completionDate":""},{"nctId":"NCT00096980","phase":"Phase 4","title":"An Open Label, Randomized, Multicenter Study to Evaluate the Safety, Tolerability, and Efficacy of Subcutaneously Administered Efalizumab Used in Combination With Topical Psoriasis Therapies for Prolo","status":"COMPLETED","sponsor":"Genentech, Inc.","isPivotal":false,"enrollment":300,"indication":"Psoriasis","completionDate":"2004-05"}],"genericFilers":[],"latestUpdates":[],"manufacturing":[],"administration":{"icon":"","route":"","frequency":"","formulation":""},"formularyStatus":[],"apiManufacturers":[],"developmentCodes":[],"ownershipHistory":[],"therapeuticAreas":["Immunology"],"biosimilarFilings":[],"firstApprovalDate":"","companionDiagnostics":[],"firstApprovalCountry":null,"genericManufacturerList":[],"modality":"Small molecule","aiSummary":"","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"partial","dataCompleteness":{"mechanism":false,"indications":true,"safety":false,"trials":true,"score":2}}